Cooley M&A

JANUARY 25, 2023

2022 drivers and headwinds Choppy access to capital markets and financing to fund ongoing operations Many life sciences companies faced challenges raising money in the capital markets in 2022. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Peak Frameworks

OCTOBER 30, 2023

This can be trading on behalf of their clients (like when you buy a stock through a bank's brokerage service) or proprietary trading where banks invest their own money. Volatile markets often lead to more trading activity as investors look to buy low and sell high. 2019 was a notable year for trading, especially for banks like J.P.

Bank 52

Bank Banking Proprietary Trading Investment Banking 52

Mergers and Inquisitions

NOVEMBER 22, 2023

The name “bulge bracket” (BB) comes from the prospectus for an IPO or debt issuance, which lists all the banks underwriting the deal. As another example, some argue that UBS should not be a bulge bracket bank because it has focused on wealth management and areas outside the capital markets.

Bulge Bracket 105

Bulge Bracket Bank Banking Boutique 105

Cooley M&A

JANUARY 22, 2021

2020 was also a blockbuster year for special purpose acquisition company (SPAC) activity, as 247 SPAC IPOs raised more than $75 billion (a 525% increase compared to the amount raised by SPAC IPOs in 2019) [3]. Creative deal terms and financing arrangements were also attractive aspects of SPAC deals as compared to their IPO cousin.

M&A 40

M&A IPO Mergers and Acquisitions Business 40

Cooley M&A

FEBRUARY 7, 2023

This post highlights 10 key trends that shaped global M&A market activity in 2022 – and will likely continue to impact deals into 2023. Show me the cash With the slowdown in capital markets, increased interest rates and the end of “easy money” from traditional lenders, the need for access to cash and financing drove M&A deals in 2022.

M&A 59

M&A Mergers and Acquisitions Mergers Finance 59

Cooley M&A

JANUARY 25, 2023

Convergence of tech and healthcare drives digital health deals As discussed in our 2022 Life Sciences M&A Year in Review blog post , decreased valuations and challenging capital markets also impacted healthcare companies last year, and digital health companies – health companies that build and sell technology – were no exception.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Cooley M&A

JANUARY 20, 2022

19 treatments from Pfizer, Merck and potentially others hitting the market soon , we expect Big Pharma to continue to parlay this cash flow into growth in other areas of strategic focus. 2021’s SPAC activity was most intense in the first quarter, with 298 SPAC IPOs priced and 97 deSPAC transactions announced in the first quarter alone.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40